Tulane to Launch Multi Center Drug Study to Improve Outcomes After Atrial Fibrillation Procedures
June 10, 2021
June 10, 2021
NEW ORLEANS, Louisiana, June 10 (TNSRes) -- Tulane University issued the following news release:
Tulane University will lead a multi center clinical trial to study whether atrial fibrillation (AFib) patients who undergo cardiac ablation to correct an irregular heart rhythm have better long-term outcomes when taking an anti-arrhythmic drug.
The trial will explore whether the drug Dronedarone helps decrease the scarring of the heart associated with the development of AFib . . .
Tulane University will lead a multi center clinical trial to study whether atrial fibrillation (AFib) patients who undergo cardiac ablation to correct an irregular heart rhythm have better long-term outcomes when taking an anti-arrhythmic drug.
The trial will explore whether the drug Dronedarone helps decrease the scarring of the heart associated with the development of AFib . . .